A long-term analysis of 620 patients with malignant melanoma at a major referral center

Surgery

Volumn 124, Issue 4, 1998, Pages 746-756

  Averbook, Bruce J ^a   Russo, Leo J ^a   Mansour, Edward G ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; THICKNESS; ULCER;

EID: 0031658075     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.1998.91269     Document Type: Article

References (22)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
3. Rigel DS. Malignant melanoma: perspectives on incidence and its effects on awareness, diagnosis, and treatment. CA Cancer J Clin 1996;46:195-8.
4. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Malignant melanoma of the skin (excluding eye). In: American Joint Committee on Cancer manual for staging of cancer. 4th ed. Philadelphia: JB Lippincott; 1992. p 143-8.
5. Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanoma of the skin. Cancer Res 1969;29:705-26.
6. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172:902-8.
7. Morton D, Davtyan D, Wanek L, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71:3737-43.
8. Soong S, Weiss HL. Predicting outcome in patients with localized melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S, editors. Cutaneous melanoma. 3rd ed. St Louis: Quality Medical Publishing, Inc; 1998. p 51-61.
9. Vollmer RT. Malignant melanoma: a multivariate analysis of prognostic factors. Pathol Annu 1989;24:383-407.
10. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 1992;8:400-14.
11. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997;15:1039-51.
12. Ross MI, Balch CM. The current management of cutaneous melanoma. Adv Surg 1991;24:139-200.
13. Balch CM, Reinigen DS, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: De Vita VT Jr, Hellman S, Rosenberg SA. editors. Cancer: principles and practice of oncology. 5th ed. Philadelphia-New York: Lippincott-Raven; 1997.
14. Urist MM. Management of patients with intermediate-thickness melanoma. Annu Rev Med 1996;47:211-7.
15. Urist MM. Surgical management of primary cutaneous melanoma. CA Cancer J Clin 1996;46:217-24.
16. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MM. A rational approach to the surgical management of melanoma. Ann Surg 1977;186:481-90.
17. Veronisi U, Adamus, J, Bandiera DC, et al. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 1982;49:2420-30.
18. Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986;61:697-705.
19. Morton DL, Wen D, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
20. Balch CM, Soong S, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255-66.
21. Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, et al. Adoptive immunotherapy with vaccineprimed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15:796-807.
22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med 1988;319:1676-80.